Joanna K. Weeks
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Joanna K. Weeks has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Austin R. Pantel
Department of Radiology, University of Pennsylvania, 3400 Spruce St, 1 Silverstein, Philadelphia, PA 19104
45 shared publications - David A. Mankoff
Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
45 shared publications - Benjamin Ferman
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania
44 shared publications - Chia-Ju Hsieh
Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
44 shared publications - Drew A. Torigian
Medical Image Processing Group, Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
44 shared publications - Fang Liu
University of Pennsylvania 5 Center for Clinical Epidemiology and Biostatistics Philadelphia, Pennsylvania
44 shared publications
Latest Publications
- 2 March 2026
- Published by Georg Thieme Verlag KG in Digestive Disease Interventions
Another Tool in the Box: The Combination of Transarterial Chemoembolization and Thermal Ablation in the Treatment of Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, which is the third-leading cause of cancer deaths worldwide. Recent updates in the Barcelona Clinic Liver Cancer (BCLC) guidelines have expanded the role of locoregional therapies to include transarterial radioembolization (TARE) along with transarterial chemoembolization (TACE) and thermal ablation. However, the selection and timing of each locoregional therapy remain a complex decision. An available approach is the combination of TACE with thermal ablation (TACE–ablate). The goal of this review is to assess the existing literature on the use of TACE–ablate for HCC. Overall, there is a suggestion of benefit in overall and progression-free survival for HCC >3 cm compared with ablation or TACE alone. Current evidence suggests ablation monotherapy is effective for tumors <3 cm while ablative-intent TARE is effective for tumors as large as 8 cm, though the median tumor size in key studies is <3 cm. The data for TACE–ablate in tumors <3 cm is mixed though it remains an option for patients with contraindications to ablation or ablative-intent radioembolization.
- 2 March 2026
- Published by Georg Thieme Verlag KG in Digestive Disease Interventions
Another Tool in the Box: The Combination of Transarterial Chemoembolization and Thermal Ablation in the Treatment of Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, which is the third-leading cause of cancer deaths worldwide. Recent updates in the Barcelona Clinic Liver Cancer (BCLC) guidelines have expanded the role of locoregional therapies to include transarterial radioembolization (TARE) along with transarterial chemoembolization (TACE) and thermal ablation. However, the selection and timing of each locoregional therapy remain a complex decision. An available approach is the combination of TACE with thermal ablation (TACE–ablate). The goal of this review is to assess the existing literature on the use of TACE–ablate for HCC. Overall, there is a suggestion of benefit in overall and progression-free survival for HCC >3 cm compared with ablation or TACE alone. Current evidence suggests ablation monotherapy is effective for tumors <3 cm while ablative-intent TARE is effective for tumors as large as 8 cm, though the median tumor size in key studies is <3 cm. The data for TACE–ablate in tumors <3 cm is mixed though it remains an option for patients with contraindications to ablation or ablative-intent radioembolization.
- 24 February 2026
- Published by Georg Thieme Verlag KG in Digestive Disease Interventions
Effectiveness of Downstaging Advanced Hepatocellular Carcinoma for Liver Transplantation: Insights from a Decade of Single-Center Experience
Unresectable patients with hepatocellular carcinoma within UNOS T2 Criteria may go directly to transplantation, but patients with disease burden exceeding T2 must first undergo downstaging treatment prior to multidisciplinary discussion of transplant eligibility. Locoregional therapy is the mainstay of downstaging therapy, which may be used in combination with resection or systemic therapy. A single-center retrospective cohort study was performed, including patients >18 years old with diagnoses of HCC not meeting T2 criteria. Patients were categorized as within the United Network for Organ Sharing Downstaging Criteria (UNOS-DS) or with disease burden beyond UNOS-DS criteria, labeled “all-comers” (AC). Exclusion criteria included mixed HCC/cholangiocarcinoma tumors and metastatic disease. All patients were outside of T2 Criteria—65 DS versus 102 AC. Patient demographics were similar between groups. The DS group was more likely to be downstaged using locoregional therapies (LRT) alone (p < 0.001) and required fewer LRT treatments to achieve downstage. Y90 was the most used LRT, followed by transarterial chemoembolization. Cumulative probability of downstage favored the DS group at all time points (p = 0.004). Overall survival was significantly different between successfully downstaged versus not downstaged patients, regardless of initial disease burden or cohort. Predictors of successful downstaging were the use of LRT and incorporation of resection when appropriate for the AC group. Predictors of poorer outcomes were alfa-fetal-protein ≥ 1,000 and the need for systemic therapy. Waitlisting rates were higher in the DS group (44.6% vs. 24.5%, p = 0.007), but once listed, transplant rates were similar (76% vs. 82%, p = 0.008) as were posttransplant survival (p = 0.250) and recurrence rates (p = 0.232). Our 10-year experience reinforces that a successful downstaging, rather than the initial tumor burden, determines survival in HCC beyond T2 criteria. While patients falling within UNOS-DS criteria achieved more successful downstaging with fewer interventions and made it to transplant more often, a selection of patients within the AC group who had a successful response to downstaging therapies also derived a meaningful benefit when transplanted.
- 24 February 2026
- Published by Georg Thieme Verlag KG in Digestive Disease Interventions
Effectiveness of Downstaging Advanced Hepatocellular Carcinoma for Liver Transplantation: Insights from a Decade of Single-Center Experience
Unresectable patients with hepatocellular carcinoma within UNOS T2 Criteria may go directly to transplantation, but patients with disease burden exceeding T2 must first undergo downstaging treatment prior to multidisciplinary discussion of transplant eligibility. Locoregional therapy is the mainstay of downstaging therapy, which may be used in combination with resection or systemic therapy. A single-center retrospective cohort study was performed, including patients >18 years old with diagnoses of HCC not meeting T2 criteria. Patients were categorized as within the United Network for Organ Sharing Downstaging Criteria (UNOS-DS) or with disease burden beyond UNOS-DS criteria, labeled “all-comers” (AC). Exclusion criteria included mixed HCC/cholangiocarcinoma tumors and metastatic disease. All patients were outside of T2 Criteria—65 DS versus 102 AC. Patient demographics were similar between groups. The DS group was more likely to be downstaged using locoregional therapies (LRT) alone (p < 0.001) and required fewer LRT treatments to achieve downstage. Y90 was the most used LRT, followed by transarterial chemoembolization. Cumulative probability of downstage favored the DS group at all time points (p = 0.004). Overall survival was significantly different between successfully downstaged versus not downstaged patients, regardless of initial disease burden or cohort. Predictors of successful downstaging were the use of LRT and incorporation of resection when appropriate for the AC group. Predictors of poorer outcomes were alfa-fetal-protein ≥ 1,000 and the need for systemic therapy. Waitlisting rates were higher in the DS group (44.6% vs. 24.5%, p = 0.007), but once listed, transplant rates were similar (76% vs. 82%, p = 0.008) as were posttransplant survival (p = 0.250) and recurrence rates (p = 0.232). Our 10-year experience reinforces that a successful downstaging, rather than the initial tumor burden, determines survival in HCC beyond T2 criteria. While patients falling within UNOS-DS criteria achieved more successful downstaging with fewer interventions and made it to transplant more often, a selection of patients within the AC group who had a successful response to downstaging therapies also derived a meaningful benefit when transplanted.
- 7 January 2026
- Published by Georg Thieme Verlag KG in Digestive Disease Interventions
Evolution of Radioembolization for Hepatocellular Carcinoma: From First Commercial Use through the State of the Art
In the 25 years since it became commercially available, yttrium 90 transarterial radioembolization has become a dominant arterial treatment modality for all stages of hepatocellular carcinoma (HCC). With lower toxicity and better, more durable oncologic outcomes than chemoembolization, radioembolization has evolved from a bail-out option in advanced disease to a disruptive competitor of percutaneous ablation and an accepted part of the Barcelona Clinic's stage-based treatment guidelines. Lobar dosimetry has evolved from single to multi-compartment models with patient-specific tumor and normal tissue dose optimization leveraging dedicated software. Radiation segmentectomy has proven safer and more effective than lobar treatment for localized HCC by sparing the majority of liver tissue any radiation exposure whatsoever. Continuing improvements in microcatheter technology and in three-dimensional angiographic image guidance and volumetry will continue to make mapping, dosing, and treating more efficient. More complete understanding of the interplay between tumor dose, tumor coverage, sphere count, and sphere radioactivity will drive routine outcomes closer to durable 100% tumor necrosis. With an eye toward the central role of dosimetry, this review aims to highlight the marquee studies leading to the current state of the art and laying the ground for radioembolization treatments of the future.
- 7 January 2026
- Published by Georg Thieme Verlag KG in Digestive Disease Interventions
Evolution of Radioembolization for Hepatocellular Carcinoma: From First Commercial Use through the State of the Art
In the 25 years since it became commercially available, yttrium 90 transarterial radioembolization has become a dominant arterial treatment modality for all stages of hepatocellular carcinoma (HCC). With lower toxicity and better, more durable oncologic outcomes than chemoembolization, radioembolization has evolved from a bail-out option in advanced disease to a disruptive competitor of percutaneous ablation and an accepted part of the Barcelona Clinic's stage-based treatment guidelines. Lobar dosimetry has evolved from single to multi-compartment models with patient-specific tumor and normal tissue dose optimization leveraging dedicated software. Radiation segmentectomy has proven safer and more effective than lobar treatment for localized HCC by sparing the majority of liver tissue any radiation exposure whatsoever. Continuing improvements in microcatheter technology and in three-dimensional angiographic image guidance and volumetry will continue to make mapping, dosing, and treating more efficient. More complete understanding of the interplay between tumor dose, tumor coverage, sphere count, and sphere radioactivity will drive routine outcomes closer to durable 100% tumor necrosis. With an eye toward the central role of dosimetry, this review aims to highlight the marquee studies leading to the current state of the art and laying the ground for radioembolization treatments of the future.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S1 from [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
PDX models treated with PARPi therapies.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S1 from [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
PDX models treated with PARPi therapies.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
Subject and Tumor Genomic Summary.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
Subject and Tumor Genomic Summary.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S6 from [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
18F]FTT-PET on subject previously treated with PARPi.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S6 from [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
18F]FTT-PET on subject previously treated with PARPi.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S4 from [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
Baseline [18F]FTT imaging correlates.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S4 from [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
Baseline [18F]FTT imaging correlates.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S2 from [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
Time between [18F]FTT imaging scans did not significantly impact SUV measurements.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S2 from [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
Time between [18F]FTT imaging scans did not significantly impact SUV measurements.